

MyHealthTest extends distribution into pharmacies

ITL Limited is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has expanded its sales distribution network by piloting distribution of its HbA1c diabetes test in pharmacies in the ACT. Sales of the test to date have been solely via MHT's online store.

Consumers will simply access the test in store and the purchase price will cover all testing costs. Availability in pharmacies will take MHT direct to its target market and potentially provide a foothold for sales of further tests MHT has in the pipeline.

ACT Pharmacist and Diabetes Educator, Elise Apolloni remarked "From a pharmacist's perspective, I think it is great that the consumer can make a decision of when to have their HbA1c levels tested, and use the kit at a time convenient from them, whether that be in the pharmacy as part of a consultation, with their GP or at home.

"Ultimately, it is about empowering the consumer to be a champion for their own health, and with the ability to test HbA1c with a kit from home, hopefully a person living with diabetes will feel motivated by the results."

MHT General Manager Nick Cerneaz stated "Giving people with diabetes improved access to our HbA1c diabetes test combined with the benefits of advice and expertise on diabetes management from the pharmacist will also lead to improved health outcomes for the many people in Australia living with this difficult condition."

Bill Mobbs
Executive Chairman

ITL Limited ABN 16 088 212 088
Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.

Australian Securities Exchange

Code: ITD

Ordinary Shares

94,438,177

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Company Secretary
David Holden	Chief Financial Officer

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles	Walbrook IR
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.com.au